Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. J Clin Oncol. 2017;35 (suppl; abstr 1000).
Overlevingsvoordeel met tebentafusp bij gemetastaseerd uveamelanoom
dec 2021 | Dermato-oncologie, Immuuntherapie